Vertebrobasilar thrombolysis with intravenous tirofiban: Case report

Journal of Thrombosis and Thrombolysis

Volumn 13, Issue 2, 2002, Pages 81-84

  Liebeskind, D S ^a   Pollard, J R ^a   Schwartz, E D ^a   Cucchiara, B L ^a   McGarvey, M L ^a   Hurst, R W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

IIb IIIa; Stroke; Thrombolysis; Tirofiban

Indexed keywords

ALBUMIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYPERTENSIVE AGENT; INFUSION FLUID; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; TYROSINE;

AGED; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BASILAR ARTERY; BLEEDING; BRAIN INFARCTION; BRAIN TOMOGRAPHY; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DAILY LIFE ACTIVITY; DRUG SELECTIVITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSMETRIA; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEMIPARESIS; HOSPITAL DISCHARGE; HUMAN; LOCKED IN SYNDROME; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RETREATMENT; RISK ASSESSMENT; TREATMENT CONTRAINDICATION; VERTEBROBASILAR INSUFFICIENCY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METHODOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; TREATMENT OUTCOME;

AGED; ARTERIAL OCCLUSIVE DISEASES; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; TYROSINE; VERTEBROBASILAR INSUFFICIENCY;

EID: 0036054843     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016242713327     Document Type: Article

References (14)

1. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome
2. Recanalization with abciximab chronicled with serial cerebral angiography
3. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development
4. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
7. Rescue treatment with abciximab in acute ischemic stroke
8. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR121787, a glycoprotein II/III antagonist
9. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes
10. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist
11. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study. The Abciximab in Ischemic Stroke Investigators
12. Thrombolysis of extracranial and intracranial arteries after IV abciximab
13. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis
14. The non-peptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke